# Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct06167694/  
OnCo record `nct06167694` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Dalpiciclib and HRS-8080 in advanced solid tumours, run by Shandong Suncadia Medicine Co., Ltd., now recruiting.

## Summary

Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastatic Breast Cancer is a phase 1/2 interventional study registered as NCT06167694 by Shandong Suncadia Medicine Co., Ltd., with 146 participants planned, started 2023-12-20 and due to reach its primary completion in 2026-06. Interventions recorded: HRS-8080; Dalpiciclib Isethionate Tablets.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06167694
- Phase: 1/2
- Setting: A Multicenter, Open Phase Ib/II Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With ER-positive, HER2-negative Unresectable or Metastatic Breast Cancer
- Sponsor: Shandong Suncadia Medicine Co., Ltd.
- Enrolled: 146

## Sources

- ClinicalTrials.gov NCT06167694: https://clinicaltrials.gov/study/NCT06167694

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Dalpiciclib](https://onco.cc/drugs/dalpiciclib/), [HRS-8080](https://onco.cc/drugs/hrs-8080/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06167694.json